The viral infectivity factor (Vif) of HIV-1 unveiled

Trends in Molecular Medicine

Volumn 10, Issue 6, 2004, Pages 291-297

  Rose, Kristine M ^a   Marin, Mariana ^a   Kozak, Susan L ^a   Kabat, David ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEASOME INHIBITOR; VIF PROTEIN;

CANCER; CELL SPECIFICITY; DEGENERATIVE DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; NONHUMAN; PROGENY; PROTEIN FUNCTION; REVIEW; UBIQUITINATION; VIRION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; GENE PRODUCTS, VIF; HIV-1; HUMANS; IMMUNITY, NATURAL; LYMPHOCYTES; MACROPHAGES; NUCLEOSIDE DEAMINASES; PROTEIN BINDING; PROTEINS; REPRESSOR PROTEINS; UBIQUITINS; VIRULENCE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 2642511413     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2004.04.008     Document Type: Review

References (70)

1. Bieniasz P.D. Restriction factors: a defense against retroviral infection. Trends Microbiol. 11:2003;286-291
2. Stremlau M., et al. The cytoplasmic body component TRIM5α restricts HIV-1 infection in Old World monkeys. Nature. 427:2004;848-853
3. Madani N., Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J. Virol. 72:1998;10251-10255
4. + T lymphocytes. J. Virol. 66:1992;6489-6495
5. Simon J.H., et al. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat. Med. 4:1998;1397-1400
6. Sheehy A.M., et al. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418:2002;646-650
7. Ochsenbauer C., et al. Analysis of vif-defective human immunodeficiency virus type 1 (HIV-1) virions synthesized in 'non-permissive' T lymphoid cells stably infected with selectable HIV-1. J. Gen. Virol. 78:1997;627-635
8. Gaddis N.C., et al. Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J. Virol. 77:2003;5810-5820
9. von Schwedler U., et al. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J. Virol. 67:1993;4945-4955
10. Courcoul M., et al. Peripheral blood mononuclear cells produce normal amounts of defective Vif-human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J. Virol. 69:1995;2068-2074
11. Goncalves J., et al. Role of Vif in human immunodeficiency virus type 1 reverse transcription. J. Virol. 70:1996;8701-8709
12. Simon J.H., Malim M.H. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J. Virol. 70:1996;5297-5305
13. Dettenhofer M., et al. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J. Virol. 74:2000;8938-8945
14. Stopak K., et al. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell. 12:2003;591-601
15. Kao S., et al. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77:2003;11398-11407
16. Mariani R., et al. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114:2003;21-31
17. Marin M., et al. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat. Med. 9:2003;1398-1403
18. Sheehy A.M., et al. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:2003;1404-1407
19. Yu X., et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 302:2003;1056-1060
20. Liu B., et al. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J. Virol. 78:2004;2072-2081
21. Teng B., et al. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science. 260:1993;1816-1819
22. Harris R.S., et al. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol. Cell. 10:2002;1247-1253
23. Jarmuz A., et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics. 79:2002;285-296
24. Lecossier D., et al. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300:2003;1112
25. Mangeat B., et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 424:2003;99-103
26. Zhang H., et al. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 424:2003;94-98
27. Shindo K., et al. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J. Biol. Chem. 278:2003;44412-44416
28. Krokan H.E., et al. Uracil in DNA-occurrence, consequences and repair. Oncogene. 21:2002;8935-8948
29. Vartanian J.P., et al. Death and the retrovirus. Trends Mol. Med. 9:2003;409-413
30. Harris R.S., et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 113:2003;803-809
31. Madani N., Kabat D. Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J. Virol. 74:2000;5982-5987
32. Yoshimura F.K., et al. Mink cell focus-forming murine leukemia virus infection induces apoptosis of thymic lymphocytes. J. Virol. 74:2000;8119-8126
33. Coffin J.M. Retroviruses. 1997;Cold Spring Harbor Laboratory Press
34. Czarneski J., et al. Mouse mammary tumor virus and the immune system. Immunol. Res. 27:2003;469-480
35. Sellon D.C., et al. Equine infectious anemia virus replication is upregulated during differentiation of blood monocytes from acutely infected horses. J. Virol. 70:1996;590-594
36. Turelli P., et al. Inhibition of hepatitis B virus replication by APOBEC3G. Science. 303:2004;1829
37. Samuel C.E. Antiviral actions of interferons. Clin. Microbiol. Rev. 14:2001;778-809
38. Conticello S.G., et al. The Vif Protein of HIV Triggers Degradation of the Human Antiretroviral DNA Deaminase APOBEC3G. Curr. Biol. 13:2003;2009-2013
39. Mehle A., et al. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J. Biol. Chem. 279:2003;7792-7798
40. Cullen B.R. Regulation of HIV-1 gene expression. FASEB J. 5:1991;2361-2368
41. Garrett E.D., et al. Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J. Virol. 65:1991;1653-1657
42. Bogerd H.P., et al. A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc. Natl. Acad. Sci. U. S. A. 101:2004;3770-3774
43. Xu H., et al. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc. Natl. Acad. Sci. U. S. A. 101:2004;5652-5657
44. Schrofelbauer B., et al. A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc. Natl. Acad. Sci. U. S. A. 101:2004;3927-3932
45. Mangeat B., et al. A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J. Biol. Chem. 279:2004;14481-14483
46. Simon J.H., et al. The regulation of primate immunodeficiency virus infectivity by Vif is cell species restricted: a role for Vif in determining virus host range and cross-species transmission. EMBO J. 17:1998;1259-1267
47. Kile B.T., et al. The SOCS box: a tale of destruction and degradation. Trends Biochem. Sci. 27:2002;235-241
48. Iwai K., et al. Identification of the von Hippel-Lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proc. Natl. Acad. Sci. U. S. A. 96:1999;12436-12441
49. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70:2001;503-533
50. Banks L., et al. Viruses and the 26S proteasome: hacking into destruction. Trends Biochem. Sci. 28:2003;452-459
51. Balzarini J., et al. Exploitation of the low fidelity of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase and the nucleotide composition bias in the HIV-1 genome to alter the drug resistance development of HIV. J. Virol. 75:2001;5772-5777
52. + T cells. J. Virol. 75:2001;7973-7986
53. Nalepa G., Wade Harper J. Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat. Rev. 29:(Suppl. 1):2003;49-57
54. Baba M., et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U. S. A. 96:1999;5698-5703
55. Strizki J.M., et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98:2001;12718-12723
56. Vassilev L.T., et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 303:2004;844-848
57. Pray T.R., et al. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist. Updat. 5:2002;249-258
58. Boutell C., Everett R.D. The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and Ubiquitinates p53. J. Biol. Chem. 278:2003;36596-36602
59. Gu H., Roizman B. The degradation of promyelocytic leukemia and Sp100 proteins by herpes simplex virus 1 is mediated by the ubiquitin-conjugating enzyme UbcH5a. Proc. Natl. Acad. Sci. U. S. A. 100:2003;8963-8968
60. Parkinson J., et al. Herpes simplex virus type 1 immediate-early protein vmw110 induces the proteasome-dependent degradation of the catalytic subunit of DNA-dependent protein kinase. J. Virol. 73:1999;650-657
61. Ulane C.M., Horvath C.M. Paramyxoviruses SV5 and HPIV2 assemble STAT protein ubiquitin ligase complexes from cellular components. Virology. 304:2002;160-166
62. Querido E., et al. Identification of three functions of the adenovirus e4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J. Virol. 75:2001;699-709
63. Scheffner M., et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1990;1129-1136
64. Boyer S.N., et al. E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res. 56:1996;4620-4624
65. Lorenzo M.E., et al. Kaposi's sarcoma-associated herpesvirus K3 utilizes the ubiquitin-proteasome system in routing class major histocompatibility complexes to late endocytic compartments. J. Virol. 76:2002;5522-5531
66. Schubert U., et al. CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J. Virol. 72:1998;2280-2288
67. Margottin F., et al. A novel human WD protein, h-β TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell. 1:1998;565-574
68. Kikkert M., et al. Ubiquitination is essential for human cytomegalovirus US11-mediated dislocation of MHC class I molecules from the endoplasmic reticulum to the cytosol. Biochem. J. 358:2001;369-377
69. VanDemark A.P., Hill C.P. Structural basis of ubiquitylation. Curr. Opin. Struct. Biol. 12:2002;822-830
70. Glickman M.H., Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82:2002;373-428